Inspiring people, place, and purpose Inspiring people, place, and purpose Penn President Amy Gutmann’s record tenure of nearly 18 years is the University’s most transformative.
Decade-long remission after CAR T cell therapy Bill Ludwig, left, was the first patient to receive CAR T cells as part of clinical trials at Abramson Cancer Center. Carl June, right, has played a pioneering roll in the therapeutic use of CAR T cells. (Image: Penn Medicine) Decade-long remission after CAR T cell therapy Two patients represent longest-known CAR T cell response to date, providing insight into treatment effect and outcomes.
Researchers find new potential targets for skin-cancer treatment Researchers find new potential targets for skin-cancer treatment Making up for the genetic mutations of MLL4 in skin cells, one of the most commonly mutated genes across all of human cancers, may keep epithelial cancer from beginning and progressing
Vaccine-like mRNA injection can be used to make CAR T cells in the body Vaccine-like mRNA injection can be used to make CAR T cells in the body An experimental immunotherapy can temporarily reprogram patients’ immune cells to attack heart fibroblast cells via only a single injection of mRNA.
This new ovarian cancer treatment could improve survival rates | 5 Questions Penn In the News Philadelphia Inquirer This new ovarian cancer treatment could improve survival rates | 5 Questions Janos L. Tanyi of the Perelman School of Medicine spoke about a large-scale trial of Cytalux, which makes cancer cells glow during surgery, being conducted at the Abramson Cancer Center. “Those patients who have all the visible cancerous lesions removed have the best survival rates,” he said. How should cancer immunotherapy be used? Penn In the News ABC Australia How should cancer immunotherapy be used? Ravi Parikh of the Perelman School of Medicine was interviewed about his research on the use of new and expensive immunotherapy medications to treat cancer patients considered to be ineligible for clinical trials. These older, sicker patients turned out be “about twice as likely to receive these novel immunotherapies compared to healthier patients who would have been included, and this is despite the fact that these drugs have never been studied in this particular group of individuals,” said Parikh. Furthermore, the study found “no survival difference” for trial ineligible patients receiving these treatments. New insights into T-cell exhaustion could improve cancer immunotherapies New insights into T-cell exhaustion could improve cancer immunotherapies A new Penn Medicine study finds that suppressing key exhaustion genes may allow CAR T cell treatments to be used much more effectively against pancreatic and other solid cancers. Improving diversity in cancer clinical trials Improving diversity in cancer clinical trials The Cancer Clinical Trials Community Ambassador Training Program at the Abramson Cancer Center was established in August 2021 to create spokespersons and resources to increase awareness and access to cancer clinical trials in the diverse Philadelphia communities. FDA approves Penn’s ‘glowing tumor’ imaging drug to identify ovarian cancer cells FDA approves Penn’s ‘glowing tumor’ imaging drug to identify ovarian cancer cells An injectable diagnostic illuminates cancer tissue that allows for greater precision during surgery was pioneered by surgeons at the University of Pennsylvania. Changing the identity of cancer cells to eliminate them New findings from a study led by the School of Veterinary Medicine’s Andrés Blanco point a way forward for the treatment of acute myeloid leukemia. (Image: National Cancer Institute) Changing the identity of cancer cells to eliminate them A team led by the School of Veterinary Medicine’s M. Andrés Blanco has uncovered a new target for treating certain blood cancers that works by removing an obstacle to their maturation. Load More
How should cancer immunotherapy be used? Penn In the News ABC Australia How should cancer immunotherapy be used? Ravi Parikh of the Perelman School of Medicine was interviewed about his research on the use of new and expensive immunotherapy medications to treat cancer patients considered to be ineligible for clinical trials. These older, sicker patients turned out be “about twice as likely to receive these novel immunotherapies compared to healthier patients who would have been included, and this is despite the fact that these drugs have never been studied in this particular group of individuals,” said Parikh. Furthermore, the study found “no survival difference” for trial ineligible patients receiving these treatments. New insights into T-cell exhaustion could improve cancer immunotherapies New insights into T-cell exhaustion could improve cancer immunotherapies A new Penn Medicine study finds that suppressing key exhaustion genes may allow CAR T cell treatments to be used much more effectively against pancreatic and other solid cancers. Improving diversity in cancer clinical trials Improving diversity in cancer clinical trials The Cancer Clinical Trials Community Ambassador Training Program at the Abramson Cancer Center was established in August 2021 to create spokespersons and resources to increase awareness and access to cancer clinical trials in the diverse Philadelphia communities. FDA approves Penn’s ‘glowing tumor’ imaging drug to identify ovarian cancer cells FDA approves Penn’s ‘glowing tumor’ imaging drug to identify ovarian cancer cells An injectable diagnostic illuminates cancer tissue that allows for greater precision during surgery was pioneered by surgeons at the University of Pennsylvania. Changing the identity of cancer cells to eliminate them New findings from a study led by the School of Veterinary Medicine’s Andrés Blanco point a way forward for the treatment of acute myeloid leukemia. (Image: National Cancer Institute) Changing the identity of cancer cells to eliminate them A team led by the School of Veterinary Medicine’s M. Andrés Blanco has uncovered a new target for treating certain blood cancers that works by removing an obstacle to their maturation.
New insights into T-cell exhaustion could improve cancer immunotherapies New insights into T-cell exhaustion could improve cancer immunotherapies A new Penn Medicine study finds that suppressing key exhaustion genes may allow CAR T cell treatments to be used much more effectively against pancreatic and other solid cancers.
Improving diversity in cancer clinical trials Improving diversity in cancer clinical trials The Cancer Clinical Trials Community Ambassador Training Program at the Abramson Cancer Center was established in August 2021 to create spokespersons and resources to increase awareness and access to cancer clinical trials in the diverse Philadelphia communities.
FDA approves Penn’s ‘glowing tumor’ imaging drug to identify ovarian cancer cells FDA approves Penn’s ‘glowing tumor’ imaging drug to identify ovarian cancer cells An injectable diagnostic illuminates cancer tissue that allows for greater precision during surgery was pioneered by surgeons at the University of Pennsylvania.
Changing the identity of cancer cells to eliminate them New findings from a study led by the School of Veterinary Medicine’s Andrés Blanco point a way forward for the treatment of acute myeloid leukemia. (Image: National Cancer Institute) Changing the identity of cancer cells to eliminate them A team led by the School of Veterinary Medicine’s M. Andrés Blanco has uncovered a new target for treating certain blood cancers that works by removing an obstacle to their maturation.